

Global Next Generation Sequencing Market Report and Forecast 2023-2031

Market Report | 2023-04-06 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Next Generation Sequencing Market Report and Forecast 2023-2031

Global Next Generation Sequencing Market Outlook

The global next generation sequencing market size reached a value of USD 9.1 billion in 2022. The market is anticipated to grow at a CAGR of 13.8% during the forecast period of 2023-2031, reaching a value of USD 29.20 billion by 2031. The growth can be attributed to the increased demand for precision medicine, advancements in sequencing technologies, and the growing application of next generation sequencing in various fields.

Global Next Generation Sequencing Market: Introduction

The global next generation sequencing market is experiencing significant growth due to factors such as technological advancements, rising demand for personalized medicine, decreasing sequencing costs, increasing government funding, and the growing application of next generation sequencing in fields like oncology, clinical diagnostics, agriculture, and forensics. Key trends in the market include the rise of single-cell sequencing, growing adoption of cloud-based solutions, and the increasing use of artificial intelligence and machine learning in data analysis. These drivers have collectively contributed to the rapid expansion of next generation sequencing technologies, transforming genomic research and enabling more accurate and efficient identification of genetic mutations, disease risk assessment, and personalized treatment plans.

Applications and Uses

Next-generation sequencing has various applications, including whole-genome sequencing, targeted resequencing, transcriptomics, metagenomics, epigenomics, and gene expression profiling. These applications enable researchers and clinicians to study genetic variation, gene expression, and epigenetic changes, contributing to a better understanding of diseases and the development of personalized therapies. The growing adoption of next-generation sequencing in clinical diagnostics, drug discovery, and precision medicine is expected to further drive the growth of the market, leading to more innovative applications and a broader impact on global healthcare.

Next Generation Sequencing Market Segmentations

The market can be categorized into types, consumables, applications, end user, and major regions:

Market Breakup by Type

- DNA Sequencing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Whole Genome Sequencing
 - o Targeted Sequencing
 - o Whole Exome Sequencing
 - o Hybridization Capture
 - o Amplicon Sequencing
 - o Molecular Inversion Probes (MIPs)
 - RNA Sequencing
 - o Whole Transcriptome Sequencing (WTS)
 - Targeted Gene Expression with RNA sequencing
 - Ribosomal RNA Depletion
 - Epigenomics
 - o ChIP-Sequencing
 - o Methyl-Sequencing
- Market Breakup by Consumables

- Sample Preparation
- o DNA Fragmentation
- o End Repair
- o A-Tailing
- o Size Selection
- o Library Preparation
- o Target Enrichment
- o Quality Control
- Other Consumables

- o Platforms
- o HiSeq
- o MiSeq
- o Ion Torrent
- o SOLiD
- o Pacbio Rs II and Sequel System
- o Other Platforms

- Market Breakup by Applications
- Drug Discovery and Development
 - Biomarker Discovery
 - Biopharmaceutical Development
 - Vaccine Development
 - Pharmacogenomics
 - Poly pharmacology
 - Pharmacoepidemiology

- Market Breakup by End User
- Clinical Research
 - Academic Research
 - Pharmaceutical and Biotechnology Companies
 - Hospitals
 - Others

- Market Breakup by Region
- North America
 - United States of America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Next Generation Sequencing Market Analysis

The global next generation sequencing market has experienced significant growth in recent years, and this trend is expected to continue in the coming years. Factors such as technological advancements, decreasing sequencing costs, increasing demand for personalized medicine, and growing application of next generation sequencing in various fields have contributed to the rapid expansion of the market.

North America, particularly the United States, holds the largest share of the global next generation sequencing market due to factors such as the presence of major market players, advanced healthcare infrastructure, and significant government funding. Europe and the Asia-Pacific regions are also expected to experience significant growth in the next generation sequencing market, driven by increasing research and development activities, growing healthcare expenditures, and rising demand for advanced diagnostic tools.

The global next generation sequencing market presents vast opportunities for growth and innovation, and it is expected to play a critical role in shaping the future of healthcare by enabling more accurate and efficient genomic research, disease risk assessment, and personalized treatment plans.

Key Players in the Global Next Generation Sequencing Market

The report gives an in-depth analysis of the key players involved in the next generation sequencing market, including manufacturers of sequencing instruments, reagents, and services. The companies included in the market are as follows:

- Illumina Inc.
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- PierianDX
- Genomatrix GmbH

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- DNASTAR, Inc.
- Perkin Elmer, Inc,
- Eurofins GATC Biotech GmbH
- Agilent Technologies, Inc.
- Danaher Corp.
- BGI Genomics

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Next Generation Sequencing Market Overview
 - 3.1 Global Next Generation Sequencing Market Historical Value (2016-2022)
 - 3.2 Global Next Generation Sequencing Market Forecast Value (2023-2031)
- 4 Global Next Generation Sequencing Market Landscape
 - 4.1 Global Next Generation Sequencing Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Next Generation Sequencing Product Landscape
 - 4.2.1 Analysis by Type
 - 4.2.2 Analysis by Applications
 - 4.2.3 Analysis by End Users
- 5 Global Next Generation Sequencing Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Global Next Generation Sequencing Market Segmentation
 - 6.1 Global Next Generation Sequencing Market by Type
 - 6.1.1 Market Overview
 - 6.1.2 DNA Sequencing
 - 6.1.2.1 Whole Genome Sequencing
 - 6.1.2.2 Targeted Sequencing
 - 6.1.2.3 Whole Exome Sequencing
 - 6.1.2.4 Hybridization Capture
 - 6.1.2.5 Amplicon Sequencing
 - 6.1.2.6 Molecular Inversion Probes (MIPs)
 - 6.1.3 RNA Sequencing
 - 6.1.3.1 Whole Transcriptome Sequencing (WTS)
 - 6.1.3.1.1 Targeted Gene Expression with RNA sequencing

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.3.1.2 Ribosomal RNA Depletion
- 6.1.3.2 Epigenomics
 - 6.1.3.2.1 ChIP-Sequencing
 - 6.1.3.2.2 Methyl-Sequencing
- 6.2 Global Next Generation Sequencing Market by Consumables
 - 6.2.1 Market Overview
 - 6.2.2 Sample Preparation
 - 6.2.2.1 DNA Fragmentation
 - 6.2.2.2 End Repair
 - 6.2.2.3 A-Tailing
 - 6.2.2.4 Size Selection
 - 6.2.2.5 Library Preparation
 - 6.2.2.6 Target Enrichment
 - 6.2.2.7 Quality Control
 - 6.2.3 Other Consumables
 - 6.2.3.1 Platforms
 - 6.2.3.2 HiSeq
 - 6.2.3.3 MiSeq
 - 6.2.3.4 Ion Torrent
 - 6.2.3.5 SOLiD
 - 6.2.3.6 Pacbio Rs II and Sequel System
 - 6.2.3.7 Other Platforms
- 6.3 Global Next Generation Sequencing Market by Applications
 - 6.3.1 Market Overview
 - 6.3.2 Drug Discovery and Development
 - 6.3.3 Biomarker Discovery
 - 6.3.4 Biopharmaceutical Development
 - 6.3.5 Vaccine Development
 - 6.3.6 Pharmacogenomics
 - 6.3.7 Poly pharmacology
 - 6.3.8 Pharmacoepidemiology
- 6.4 Global Next Generation Sequencing Market by End User
 - 6.4.1 Market Overview
 - 6.4.2 Clinical Research
 - 6.4.3 Academic Research
 - 6.4.4 Pharmaceutical and Biotechnology Companies
 - 6.4.5 Hospitals
 - 6.4.6 Others
- 6.5 Global Next Generation Sequencing Market by Region
 - 6.5.1 Market Overview
 - 6.5.2 North America
 - 6.5.3 Europe
 - 6.5.4 Asia Pacific
 - 6.5.5 Latin America
 - 6.5.6 Middle East and Africa
- 7 North America Next Generation Sequencing Market
 - 7.1 Market Share by Country

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2 United States of America
- 7.3 Canada
- 8 Europe Next Generation Sequencing Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Next Generation Sequencing Market
 - 9.1 Market Share by Country
 - 9.2 China
 - 9.3 Japan
 - 9.4 India
 - 9.5 ASEAN
 - 9.6 Australia
 - 9.7 Others
- 10 Latin America Next Generation Sequencing Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Next Generation Sequencing Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Funding Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
 - 15.1 Analysis by Partnership Instances
 - 15.2 Analysis by Type of Partnership
 - 15.3 Analysis by Leading Players
 - 15.4 Analysis by Geography
- 16 Regulatory Framework
 - 16.1 Regulatory Overview
 - 16.1.1 US FDA
 - 16.1.2 EU EMA
 - 16.1.3 INDIA CDSCO
 - 16.1.4 JAPAN PMDA
 - 16.1.5 Others
- 17 Supplier Landscape
 - 17.1 Illumina Inc.
 - 17.1.1 Financial Analysis
 - 17.1.2 Financial Portfolio
 - 17.1.3 Demographic Reach and Achievements
 - 17.1.4 Mergers and Acquisitions
 - 17.1.5 Certifications
 - 17.2 F. Hoffmann-La Roche Ltd.
 - 17.2.1 Financial Analysis
 - 17.2.2 Financial Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisitions
 - 17.2.5 Certifications
 - 17.3 Thermo Fisher Scientific, Inc.
 - 17.3.1 Financial Analysis
 - 17.3.2 Financial Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisitions
 - 17.3.5 Certifications
 - 17.4 Bio-Rad Laboratories, Inc.
 - 17.4.1 Financial Analysis
 - 17.4.2 Financial Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisitions
 - 17.4.5 Certifications
 - 17.5 PierianDX
 - 17.5.1 Financial Analysis
 - 17.5.2 Financial Portfolio
 - 17.5.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Genomatrix GmbH
 - 17.6.1 Financial Analysis
 - 17.6.2 Financial Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisitions
 - 17.6.5 Certifications
- 17.7 DNASTAR, Inc.
 - 17.7.1 Financial Analysis
 - 17.7.2 Financial Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisitions
 - 17.7.5 Certifications
- 17.8 Perkin Elmer, Inc.
 - 17.8.1 Financial Analysis
 - 17.8.2 Financial Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisitions
 - 17.8.5 Certifications
- 17.9 Eurofins GATC Biotech GmbH
 - 17.9.1 Financial Analysis
 - 17.9.2 Financial Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisitions
 - 17.9.5 Certifications
- 17.10 Agilent Technologies, Inc.
 - 17.10.1 Financial Analysis
 - 17.10.2 Financial Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisitions
 - 17.10.5 Certifications
- 17.11 Danaher Corp.
 - 17.11.1 Financial Analysis
 - 17.11.2 Financial Portfolio
 - 17.11.3 Demographic Reach and Achievements
 - 17.11.4 Mergers and Acquisitions
 - 17.11.5 Certifications
- 17.12 BGI Genomics
 - 17.12.1 Financial Analysis
 - 17.12.2 Financial Portfolio
 - 17.12.3 Demographic Reach and Achievements
 - 17.12.4 Mergers and Acquisitions
 - 17.12.5 Certifications
- 18 Global Next Generation Sequencing Market - Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
 - 20.1 Very Small Companies
 - 20.2 Small Companies
 - 20.3 Mid-Sized Companies
 - 20.4 Large Companies
 - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Next Generation Sequencing Market Report and Forecast 2023-2031

Market Report | 2023-04-06 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com